Participants in the study will receive an injection of a solution called Radelumin, which contains a substance that helps highlight areas of cancer during the PET/CT scan. The study will compare the results of the PET/CT scans with the findings from a biopsy, which is a procedure where a small sample of tissue is taken from the body to be examined under a microscope. This comparison will help determine the accuracy of the PET/CT scans in identifying cancer spread.

The study will be conducted over a period of time, during which participants will undergo the PET/CT scan and have their results analyzed by three independent experts who are not aware of the patients’ clinical information. This approach ensures an unbiased assessment of the imaging technique’s effectiveness. The study aims to provide valuable information that could improve the diagnosis and treatment planning for patients with high-risk prostate cancer.

The purpose of the study is to explore whether this treatment switch can improve the PSA response in this setting. In the study, participants first receive the standard hormone-based treatment, and then treatment is changed to BMS-986365. The study then follows how the cancer and symptoms change over time, while also checking for side effects, blood test changes, and heart tracing changes. The study also looks at general health and pain over the course of treatment.

The purpose of this study is to find out if xaluritamig can help people live longer compared to the other treatment options. Xaluritamig is given as an infusion into a vein, which means it is delivered directly into the bloodstream through a needle. Some people in the study may also receive siltuximab, which is another medicine given through a vein that may help manage certain side effects. The study will also look at whether the cancer stops growing or shrinking, how long any improvements last, whether bone problems are delayed, and how the treatments affect pain and quality of life. Additionally, the study will monitor any unwanted effects or side effects that occur during treatment and will measure how the body processes xaluritamig and whether the body develops any immune response to it.

People joining this study will be randomly assigned to receive either xaluritamig or one of the other treatment options chosen by their doctor. Throughout the study, participants will have regular check-ups that include scans to see how the cancer is responding, blood tests to check overall health and levels of a substance called prostate-specific antigen, and questionnaires to understand how they are feeling and how the treatment is affecting their daily life. The study will continue for several years to gather enough information about how well the treatments work and how safe they are.

Participants will receive dexamethasone at different times during the study to measure how much of the medicine stays in the blood. The first measurement will be taken before starting the antihormonal therapy, and then again after the body has adjusted to the regular use of enzalutamide or apalutamide. Blood samples will be collected to measure the amount of dexamethasone present over time, which helps researchers understand if the antihormonal medicines are affecting how the body breaks down the glucocorticoid. Later in the study, participants may receive a higher dose of dexamethasone to see if increasing the amount can make up for any changes caused by the antihormonal treatment.

The study will also look at whether any unwanted effects occur when dexamethasone is given on three separate occasions during the treatment period. Researchers want to understand if the combination of these medicines requires any adjustments to dosing to ensure patients receive the full benefit of their corticosteroid treatment while taking their cancer therapy. The information gathered will help doctors better understand how these medicines interact in the body and whether treatment plans need to be modified when these medications are used together.

The purpose of the study is to find out if adding Saruparib to the standard treatment of radiotherapy and androgen deprivation therapy can help men with this type of prostate cancer live longer without the cancer spreading to distant parts of the body compared to placebo. The study will measure how long participants remain free of distant spread of cancer, which is called metastases-free survival, and will also look at overall survival and other measures of how well the treatment works. During the study, participants will receive the study medication in tablet form taken by mouth, and they will need to have various scans including computed tomography or magnetic resonance imaging, bone scans, and prostate-specific membrane antigen-positron emission tomography scans to check for any signs of cancer spread.

Participants will be randomly assigned to receive either the active study medication or placebo in addition to their standard treatment, and neither the participants nor their doctors will know which treatment they are receiving during the study. The study requires tissue samples from the prostate cancer to confirm the presence of the BRCA gene mutation before enrollment. Throughout the study, participants will be monitored for how the treatment affects their cancer, their overall health, and their quality of life through questionnaires about symptoms and daily functioning. Blood samples will also be collected to measure the levels of the study medication in the body and to understand how it works.

During the study, patients will undergo PSMA PET/CT scans, which are special imaging tests that combine two types of scans to find and measure prostate cancer in the body. These scans will be done before starting the treatment and again after taking darolutamide to compare the results. The study will look at whether the number of cancer deposits increases, whether existing cancer spots show higher levels of the PSMA protein, or whether the cancer spots become larger or more visible after treatment with darolutamide. This effect, where the visibility of cancer temporarily increases after starting certain hormone-blocking treatments, is sometimes called a flare phenomenon.

Patients participating in this study will have already received previous treatment for their prostate cancer, either surgery to remove the prostate or radiation therapy, and their scans will show between one and five areas where the cancer has spread to bones or lymph nodes. The study will also collect information about any side effects that occur and how patients feel during the treatment by using quality of life questionnaires. The measurements taken during the scans will include the number of cancer spots, their size, their location in the body, and a measurement called SUVmax which indicates how much the PSMA protein is present in each spot.

The purpose of this study is to find out if the combination of xaluritamig plus abiraterone helps people with this type of prostate cancer live longer compared to the treatment chosen by their doctor. The study will also look at how long the cancer stays under control, whether the cancer shrinks or disappears, how long any improvement lasts, and how the treatments affect quality of life and symptoms such as pain. Additionally, the study will check for any unwanted effects of the treatments and measure how the body processes these medicines over time.

Participants in this study will be randomly assigned to receive either the combination of xaluritamig plus abiraterone or one of the treatments chosen by their doctor. During the study, participants will have regular check-ups where doctors will use imaging tests like computed tomography scans, magnetic resonance imaging scans, or bone scans to see how the cancer is responding to treatment. Blood tests will be done to check organ function and measure levels of prostate-specific antigen, which is a substance in the blood that can indicate how the cancer is responding. Participants will also be asked to complete questionnaires about their pain levels, side effects, and overall quality of life throughout the study. The study will continue until enough information is collected to determine which treatment approach works better.

The purpose of the study is to find the best and safest dose of GSK5458514 and to check how well it is tolerated by participants. The study will look at any side effects that occur and will measure how the body processes the medication. Participants in this study will be men who have already received other treatments for their prostate cancer, including hormone therapy and chemotherapy with taxane-based medications, but whose cancer has continued to progress. The study will also check if the treatment helps to reduce the level of prostate-specific antigen, which is a substance in the blood that can indicate how the cancer is responding, and whether tumors shrink or stop growing.

During the study, participants will receive the medication and will be monitored closely through regular visits where doctors will perform physical examinations, blood tests, and imaging scans such as CT scans, MRI, or bone scans to see how the cancer is responding. The study will collect tissue samples from previous biopsies or may request a new biopsy to analyze the cancer cells and look for specific markers. Participants will need to continue their testosterone-lowering therapy throughout the study and must meet certain health requirements to be eligible. The study will track any side effects and changes in the cancer to understand how safe and effective GSK5458514 is for treating this type of prostate cancer.

The study is divided into three groups of people. The first group includes people whose cancer has spread and no longer responds to hormone treatments. These people will receive either ASP5541 with a steroid or abiraterone acetate with a steroid. The second group includes people whose cancer has spread but still responds to hormone treatments. Some people in this group will receive ASP5541 without steroids, while others will receive abiraterone acetate with steroids. The third group includes people from Japan with either type of prostate cancer who will receive ASP5541 with steroids. All people in the study will continue to receive treatments that keep male hormone levels low.

During the study, doctors will measure a substance in the blood called PSA, which is a marker for prostate cancer activity. They will check how much the PSA levels drop and whether they become very low or undetectable. Doctors will also use imaging tests such as CT scans, MRI scans, and bone scans to see if the cancer grows or shrinks. The study will monitor how long it takes before the cancer gets worse and will track any side effects that people experience. Safety checks will include blood tests, heart tests called electrocardiograms, blood pressure measurements, and general physical examinations. The study will also ask people to complete questionnaires about their pain levels and overall well-being.

The purpose of this study is to determine if combining these chemotherapy drugs with precisely targeted radiation therapy (called stereotactic ablative radiotherapy) can help control cancer that has spread to a limited number of locations in the body. The treatment involves receiving chemotherapy through an intravenous infusion, along with radiation therapy directed at specific tumor sites identified through specialized imaging scans.

This is a two-phase study where doctors first evaluate the safety of this treatment combination, and then assess how well it works at controlling the cancer. The study is designed for patients who have already tried other standard treatments and have limited remaining treatment options. The treatment approach aims to target both widespread disease with chemotherapy and specific tumor sites with focused radiation therapy.

The purpose of the study is to compare the outcomes of radiation treatment when planned using PSMA PET imaging versus standard imaging methods. The study involves two groups of patients – one group will receive radiation therapy planned using conventional imaging, while the other group will have their treatment planned using PSMA PET scans. Each participant will receive a single dose of the imaging agent before their radiation treatment planning.

During the study, patients will be monitored for several years to track their response to treatment and any changes in their cancer status. The monitoring includes regular check-ups and various tests to assess how well the treatment is working. The study medication (Locametz) is already approved for use in medical imaging and will be given as a single dose of up to 259 MBq (a measure of radioactivity).

The purpose of this study is to evaluate the recovery of erectile function (the ability to achieve and maintain an erection) six months after completing hormonal therapy. Hormonal therapy for prostate cancer works by reducing male hormones (androgens) that can stimulate cancer growth, but may cause side effects including erectile dysfunction (difficulty achieving or maintaining an erection).

During the study, participants will receive treatment and then be monitored through regular follow-up visits and questionnaires that assess erectile function, urinary and rectal symptoms, and overall quality of life. The study will also examine factors that might influence erectile function recovery, such as radiation doses to specific anatomical structures like the penile bulb, neurovascular bundles (nerves and blood vessels around the prostate that control erections), and other surrounding tissues.

The trial is a first-in-human study, meaning this treatment has not been tested in people before. It involves taking a sample of the patient’s tumor tissue through surgery, extracting the tumor-infiltrating lymphocytes, growing them in a laboratory to increase their numbers, and then returning these cells to the patient as a form of treatment. Patients will receive multiple administrations of the CC-38 treatment over the course of the study.

To participate, patients must have colorectal cancer that has spread to other parts of the body (stage IV) or prostate cancer that is either locally advanced (stage III) or has spread to other parts of the body (stage IV). Their disease must have progressed despite previous standard treatments, and they must have measurable disease remaining after the tumor sample is taken for creating the treatment.

Participants in this study will undergo robot-assisted laparoscopic prostatectomy (a minimally invasive surgical procedure to remove the prostate) with extended pelvic lymph node dissection (removal of lymph nodes from the pelvic area). Before surgery, patients will receive an injection of the 99mTc-hPSMA tracer. During the operation, the surgeon will use special instruments to detect both the radioactive and fluorescent signals from the tracer, which should concentrate in cancerous areas. This may help the surgeon to better identify and remove all cancer tissue while preserving healthy tissue.

The study will evaluate how well the tracer works for identifying cancer in the prostate and lymph nodes, comparing what is seen during surgery with the results of laboratory examination of the removed tissue. It will also track any side effects from the tracer for 14 days after injection and measure PSA (prostate specific antigen, a blood test marker for prostate cancer) levels after surgery to assess outcomes.

The purpose of the study is to assess the effectiveness of a genomic biomarker called PCAI ImmunoScore in predicting the response of prostate cancer to treatment with Darolutamide before surgery to remove the prostate, known as a radical prostatectomy. The study will observe how well the cancer responds to the treatment by looking at the amount of cancer left after treatment, referred to as minimal residual disease (MRD). Participants will take Darolutamide for a period of 90 to 120 days before undergoing surgery.

Throughout the study, researchers will also examine various factors such as changes in tumor size, blood levels of a protein called PSA (prostate-specific antigen), and any side effects related to hormone levels. The study aims to provide insights into how well the PCAI ImmunoScore can predict treatment outcomes and help tailor future treatments for prostate cancer patients. Participants will be monitored for changes in their condition and any side effects during and after the treatment period.

The purpose of the study is to determine which approach is more effective in helping men achieve good unassisted erections 24 months after surgery. Participants will be followed for a total of 24 months, with regular check-ins to monitor their progress. The study will also look at other aspects of sexual health and quality of life, such as orgasmic function, feelings of masculinity, and the impact on partners. The trial will include the use of questionnaires to gather information on these topics.

In addition to sildenafil, another treatment option being studied is Androskat, which is a solution for injection containing two active substances: phentolamine mesilate and papaverine hydrochloride. This treatment is administered through an injection directly into the penis. The study will compare the effectiveness and side effects of these treatments to determine the best approach for penile rehabilitation after prostate cancer surgery.

Participants in the study will receive the treatment, and the researchers will monitor how well the SpectraCure P18 System can deliver and control the necessary light dose to treat the cancer. The study will also determine the safest and most effective light dose by observing responses through MRI scans and any side effects that may occur. The trial will involve regular follow-ups to check the progress of the treatment and to ensure the safety of the participants.

Throughout the study, the effectiveness of the treatment will be evaluated by checking for the absence of cancer cells in the prostate through biopsies at different intervals. The study aims to provide valuable information on whether this combination of the SpectraCure P18 System and verteporfin can be a safe and effective option for treating primary localized prostate cancer.

The purpose of the study is to see how well this combination treatment works in reducing the levels of a protein called PSA (prostate-specific antigen) in the blood, which is an indicator of prostate cancer activity. Participants in the study will receive a short course of oral Relugolix along with the radiation therapy over a period of six months. The study will also look at other outcomes, such as how long patients remain free from cancer returning, how quickly testosterone levels recover after treatment, and the impact on quality of life.

Throughout the study, researchers will monitor various aspects of health, including the occurrence of any fractures, cardiovascular events like heart attacks or strokes, and any changes in erectile function. The study aims to provide valuable information on the effectiveness and safety of this treatment approach for men with intermediate risk prostate cancer.

Participants in the study will receive the 99mTc-PSMA-T4 treatment through an injection. The study will monitor how the treatment helps in diagnosing and planning treatment for prostate cancer and its spread to other parts of the body, known as metastases. The study will also keep track of any side effects that might occur after the treatment is given. The goal is to see if this method can accurately detect cancerous areas and help in making treatment decisions.

The study will take place over a period of time, during which participants will be closely observed to ensure their safety and to gather information on the effectiveness of the treatment. The results will help determine if 99mTc-PSMA-T4 is a feasible and safe option for diagnosing and planning treatment for prostate cancer. This research could potentially lead to better ways of managing prostate cancer in the future.

The main purpose is to determine if the new imaging method using 99mTc-MIP-1404 is better at finding cancer that has spread to nearby lymph nodes compared to current standard imaging methods. The study involves receiving an injection of one of these imaging substances through a vein, followed by body scanning. Each participant will undergo different types of scans to compare how well each method works in detecting cancer spread.

All imaging substances used in this study are specially designed to attach to cancer cells, making them visible during scanning. These scans help doctors understand if the cancer is confined to the prostate or has spread to other areas. This information is important for determining the most appropriate treatment approach for each person’s specific situation.

Two medications are being used in this study. The first is Decapeptyl, which contains the active substance triptorelin and is administered as a prolonged-release injection under the skin. The second medication is Casodex, which contains the active substance bicalutamide and is taken orally as a film-coated tablet. These medications are part of the ADT treatment being tested in combination with SBRT.

The purpose of the study is to determine if there is an improvement in the time patients remain free from signs of cancer after treatment, known as biochemical disease-free survival (bDFS). Participants in the study will receive either SBRT alone or SBRT combined with ADT. The trial will monitor patients over time to assess the effectiveness of these treatments in preventing cancer recurrence and improving overall survival. The study is expected to continue until 2029.

Participants in the study will receive the treatment and be monitored over time to see how the cancer responds. The study will look at changes in PSMA levels, particularly in bone lesions compared to prostate lesions, after starting the treatment. This will help researchers understand if the treatment causes a noticeable change in PSMA levels, which could indicate how the cancer is reacting to the therapy.

Throughout the study, additional tests such as PET scans will be used to track the cancer’s progression and response to the treatment. Researchers will also explore other aspects, such as changes in hormone levels and the gut microbiome, which is the collection of bacteria and other microorganisms in the digestive system, during the course of the treatment. The study aims to provide valuable insights into the effectiveness of degarelix in treating metastatic prostate cancer and its impact on PSMA expression.

The purpose of the study is to evaluate how well the treatment controls the disease and to assess its safety. Participants in the study will receive the treatment and be monitored over a period of time to see how their tumors respond. The study will also look at any side effects that may occur during and after the treatment. The treatment period can last up to 24 weeks, and participants will have regular check-ups to monitor their health and the progress of their disease.

This study is designed to include patients with different types of tumors that have been confirmed to be PSMA-positive. The goal is to see if this treatment can be effective across various cancer types. The study will also track how long patients live after starting the treatment and how long it takes for the disease to progress. This information will help determine the potential benefits and risks of using 177Lu-PSMA I&T for treating advanced cancers.

The purpose of the study is to determine which imaging method is more accurate in identifying cancer spread. Participants will undergo both imaging tests. The 64CuCl2 solution for injection and Fluorocholine (18F) solution for injection are used in these tests to help highlight areas of potential cancer spread. The study will assess how well each method detects cancer in different parts of the body, such as bones, lymph nodes, and other organs.

Throughout the study, the impact of these imaging tests on treatment decisions will be evaluated. This includes understanding how the results might change the course of treatment for patients. The study will also look at how these imaging methods relate to levels of a protein called PSA, which is often higher in men with prostate cancer. The goal is to improve the accuracy of cancer detection and help guide better treatment decisions for those with prostate cancer.

Participants in the study will receive the treatment [177Lu]Lu-PSMA-I&T through an injection into a vein. The study will also use a special imaging technique called [68Ga]Ga-PSMA-11 PET to help diagnose and monitor the cancer. This imaging method helps doctors see where the cancer is located in the body. The study will observe how the cancer responds to the treatment and how it affects the participants’ health over time.

The purpose of the study is to evaluate the effects of the treatment on the cancer and to ensure it is safe for patients. The study will monitor the participants’ health and any side effects they may experience. The goal is to gather information that could help improve treatment options for patients with prostate cancer in the future.

The study involves three different treatments: 18F-PSMA-1007, PIFLUFOLASTAT (18F), and Locametz 25 micrograms kit for radiopharmaceutical preparation. These are solutions that are injected into the body to help highlight cancer cells during the PSMA PET/CT scan. The trial will compare the results of using these imaging agents with the current standard practice, which involves performing ePLND based on a calculated risk of cancer spread. The study will monitor various outcomes, including the rate of cancer returning after surgery and any complications related to the procedures.

Participants in the study will undergo PSMA PET/CT scans and may receive one of the imaging agents through an intravenous injection. The trial will track the number of surgical procedures performed, the costs associated with these interventions, and any complications that arise. The study will also assess the number of lymph nodes removed during surgery and whether additional PSMA PET/CT scans are needed. The trial is expected to continue until June 2030, with the aim of providing valuable insights into the cost-effectiveness and patient impact of using PSMA PET/CT in the management of prostate cancer.

The purpose of the study is to evaluate how well the 64Cu-PSMA I&T PET/CT scan can identify whether prostate cancer has spread to the pelvic lymph nodes in men who have been newly diagnosed with unfavorable intermediate-risk, high-risk, or very high-risk prostate cancer. These men are planning to undergo surgery to remove the prostate and some of the surrounding lymph nodes. The study will help determine if the scan can accurately show the presence or absence of cancer in these lymph nodes.

Participants in the study will receive an injection of 64Cu-PSMA I&T and then undergo a PET/CT scan. This scan combines two imaging techniques to provide detailed pictures of the inside of the body. The study will monitor any side effects from the injection for up to 72 hours. The results of the scan will be compared to the findings from the surgery to see how well the scan can detect cancer spread. This research aims to improve the way prostate cancer is staged and treated in the future.

The purpose of the study is to evaluate how accurately the 64CuCl2 PET/CT scan can detect the return of prostate cancer in patients who have already had surgery and show signs of the disease coming back, as indicated by rising levels of a protein called PSA in their blood. This imaging method is being tested to see if it can find cancer that other traditional methods might miss. The study involves patients who have had a previous diagnosis of prostate cancer and have undergone surgery to remove the prostate, but now show signs of the disease returning.

Participants in the study will receive an injection of the 64CuCl2 solution, which is a type of imaging agent, and then undergo a PET/CT scan. The results of this scan will help doctors determine if there is a local recurrence of cancer in the prostatic bed. The study will also look at how the scan results might influence treatment decisions, such as whether to proceed with radiation therapy. The trial aims to provide valuable information on the effectiveness of this imaging technique in guiding treatment for patients with recurrent prostate cancer.

The purpose of the study is to determine if the combination of Fuzuloparib with AA-P is more effective than a placebo combined with AA-P as a first-line treatment for patients with mCRPC. Participants in the study will be randomly assigned to receive either the Fuzuloparib combination or the placebo combination. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medications orally, as they are in the form of tablets or capsules. The study will monitor the progression of the cancer and assess the overall health and survival of the participants. The trial aims to provide valuable information on whether adding Fuzuloparib to the existing treatment can offer better outcomes for patients with this challenging form of prostate cancer.

The purpose of the study is to evaluate how well the treatment works by measuring the response of a protein called prostate specific antigen (PSA) in the blood, which is an indicator of prostate cancer activity. The study will also assess the safety of the treatment by monitoring any side effects that may occur. Participants will receive the treatment through an injection into a vein, and the study will take place over a period of time to observe the effects of the treatment.

Throughout the study, participants will undergo regular check-ups to monitor their health and the effectiveness of the treatment. The goal is to determine if this new therapy can help manage prostate cancer in patients who have shown signs of the disease returning after their initial treatment. The study aims to provide valuable information that could lead to improved treatment options for prostate cancer in the future.

The purpose of the study is to assess how safe and feasible it is to use these treatments alternately in patients who have already received curative therapy, such as surgery or radiation, for their prostate cancer. Participants will receive these treatments in a specific sequence, and the study will monitor how well they tolerate the treatments and any side effects they may experience. The study will also look at how these treatments affect the patients’ quality of life and the progression of their cancer over time.

Throughout the study, participants will undergo regular assessments to check their health and the status of their cancer. This includes monitoring their prostate-specific antigen (PSA) levels, which is a marker used to track prostate cancer, and using imaging tests like PET/CT scans to see how the cancer responds to the treatment. The study aims to provide valuable information on the potential benefits and risks of using these radioligand therapies in treating prostate cancer that has spread to the bones.

The purpose of this research is to determine how well a special type of imaging called Positron Emission Tomography (combined with Computed Tomography) can detect whether cancer has spread to lymph nodes in patients with intermediate or high-risk prostate cancer. This imaging technique uses a substance that specifically attaches to prostate cancer cells, making them visible during the scan.

During the study, participants will receive an injection of the imaging agent and undergo a scanning procedure. The results of these scans will be compared with findings from surgery and other standard tests. The imaging will help doctors determine if cancer cells have spread beyond the prostate, which is important information for planning surgery and other treatments.

The purpose of the study is to determine if the combination of SHR3680 and ADT is more effective than the combination of Bicalutamide and ADT in improving the time patients live without the cancer getting worse, known as radiological progression-free survival, and overall survival. Participants in the study will receive one of these treatment combinations and will be monitored over a period to assess the effectiveness and safety of the treatments. The study will also look at other factors such as the time it takes for prostate-specific antigen (PSA) levels to rise, the time to the next bone-related event, and the time to the start of the next prostate cancer treatment.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the progress of the cancer. The study aims to provide valuable information on the best treatment options for patients with this type of prostate cancer, potentially leading to improved outcomes and quality of life for those affected by the disease.

The trial will include patients with various types of advanced cancers, such as non-small cell lung cancer, renal cell carcinoma, urothelial bladder cancer, head and neck squamous cell cancer, breast cancer, gastric or gastroesophageal adenocarcinoma, epithelial ovarian cancer, cervical cancer, endometrial adenocarcinoma, prostate cancer, and soft tissue sarcoma. The study will be conducted in two phases. The first phase will focus on finding the right dose of JK06 by gradually increasing the amount given to patients. The second phase will involve giving the selected dose to more patients to further evaluate its effects.

Throughout the study, patients will receive the treatment every three weeks and will be monitored closely for any side effects or changes in their condition. The goal is to gather information that will help in developing JK06 as a potential treatment option for people with these types of advanced cancers. The study is expected to continue until 2028, with recruitment starting in 2024.

The purpose of the study is to evaluate the safety and effectiveness of these treatments. Participants will be randomly assigned to one of the treatment groups and will receive their assigned treatment for a period of up to 90 days. The study will monitor the participants’ health and the progression of their prostate cancer during this time. The trial aims to determine which treatment approach is most effective in managing the disease.

Throughout the study, participants will undergo regular check-ups and assessments to track their response to the treatment. The study will also compare the outcomes of the different treatment groups to understand the benefits and potential side effects of each approach. This research is important for improving treatment options for men with high-risk nonmetastatic prostate cancer.

The purpose of the study is to evaluate how well these treatments work and how safe they are for patients. Participants will receive one or more of these medications, and their health will be monitored closely throughout the study. The study will also look at how the treatments affect levels of prostate-specific antigen (PSA), a substance in the blood that can indicate the presence of prostate cancer. The study will be conducted over several years, with regular check-ups and assessments to track the progress of the disease and any side effects experienced by participants.

By participating in this study, researchers hope to gather important information that could lead to better treatment options for those with advanced prostate cancer. The study will help determine the best doses and combinations of these medications to improve patient outcomes. The ultimate goal is to find effective ways to manage and treat metastatic castration-resistant prostate cancer, providing hope for patients and their families.

The purpose of the study is to determine if combining ADT with radiotherapy can help delay the progression of cancer in patients with a limited number of metastases, which are small areas where the cancer has spread. Participants in the study will receive either the combination of ADT and radiotherapy or radiotherapy alone. The study will last for a period of six months, during which the effects of the treatments will be monitored.

The main goal is to see if the combination treatment can extend the time patients remain free from further cancer spread. Additionally, the study will look at other factors such as the quality of life, the time until further treatment is needed, and the overall survival of the patients. The trial will also assess the sensitivity of imaging techniques like PSMA-PET/CT or PSMA-PET/MRI used to detect cancer spread. The study is expected to conclude by the end of 2025.

Participants in the study will receive either darolutamide or a placebo, in addition to their regular treatment. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not biased. The main focus of the study is to determine if the treatment can help patients live longer without the cancer spreading, which is referred to as metastasis-free survival.

The study will also look at other important outcomes, such as overall survival, which is the length of time patients live after starting the study, and prostate cancer-specific survival, which is the time patients live without dying from prostate cancer. Additionally, the study will monitor the progression of prostate-specific antigen (PSA) levels, which are used to track prostate cancer, and the time it takes for the cancer to become resistant to hormone therapy. The study will also assess the quality of life of participants and any side effects they may experience during the trial.

Participants in the study will receive either the radioligand therapy alone or in combination with the immunotherapy. The study will monitor the ability to perform surgery on the prostate after the treatment, as well as the response of the cancer to the treatment. The study will also track any side effects experienced by participants and how long they remain free from cancer progression after surgery.

The trial is expected to run until 2027, with recruitment starting in 2024. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the effectiveness of the treatments. This study aims to provide valuable insights into new treatment options for men with very high-risk prostate cancer.

The purpose of the study is to evaluate the benefits of adding apalutamide to the existing treatment regimen for patients who have experienced a return of prostate cancer after surgery. Participants in the study will receive either the combination of apalutamide, radiotherapy, and hormone therapy or a placebo along with radiotherapy and hormone therapy. The study will monitor the participants over a period of time to assess how well the treatment works in preventing the cancer from progressing.

Throughout the study, participants will undergo regular check-ups and tests to track their health and the status of their cancer. The study aims to determine if the addition of apalutamide can improve the length of time patients remain free from cancer progression. The results will help to understand the potential benefits of this treatment combination for individuals with high-risk prostate cancer that has returned after surgery.